Preventing cervical cancer in HIV-positive women in Mexico and Puerto Rico
CAMPO Clinical Trials Program
This study is looking for ways to help prevent cervical cancer in women with HIV in Mexico and Puerto Rico by testing new screening methods, exploring the benefits of probiotics, and trying out a new vaccine to treat cervical and anal lesions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11177201 on NIH RePORTER |
What this research studies
The CAMPO Clinical Trials Program focuses on preventing cervical cancer among HIV-positive women in Mexico and Puerto Rico through three clinical studies. The first study will test new screening methods for detecting high-grade cervical lesions in 4,000 women. The second study will explore the effects of probiotics on the microbiota and their potential to help reduce lesions and HPV persistence in 600 participants. The third study will assess the safety and effectiveness of a new therapeutic vaccine aimed at treating cervical and anal lesions in 300 HIV-positive individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research are HIV-positive women and men living in Mexico and Puerto Rico, particularly those at risk for cervical and anal cancer.
Not a fit: Patients who are not HIV-positive or those who do not reside in Mexico or Puerto Rico may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved screening and treatment options for cervical cancer in HIV-positive women, potentially reducing cancer rates.
How similar studies have performed: Previous research has shown promise in using probiotics and therapeutic vaccines for cancer treatment, indicating potential success for this approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Palefsky, Joel Michael — University of California, San Francisco
- Study coordinator: Palefsky, Joel Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.